MétaCan
Menu
Back to cohort
Record W4409077337 · doi:10.1136/bmjgast-2024-001615

Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

2025· article· en· W4409077337 on OpenAlexafffundabout
Siddharth Singh, J. Nguyen, David Fudman, Mark E. Gerich, Shiraz A. Shah, David Hudesman, Ryan McConnell, Dana J. Lukin, Ann D. Flynn, Caroline Hwang, Brandon Sprung, Jill Gaidos, Mark Mattar, David T. Rubin, Jana G. Hashash, Mark Metwally, Tauseef Ali, Christopher Ma, Frank Hoentjen, Neeraj Narula, Talat Bessissow, Greg Rosenfeld, Jeffrey D. McCurdy, Ashwin N. Ananthakrishnan, Raymond Cross, Josep María Gaytán, Sagar Patel, Corey A. Siegel, Gil Melmed, Sarah Weaver, Sydney Power, Guangyong Zou, Vipul Jairath, Jason K. Hou

Bibliographic record

VenueBMJ Open Gastroenterology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsWestern UniversityOttawa HospitalUniversity of British ColumbiaUniversity of OttawaMontreal General HospitalMcMaster UniversityPopulation Health Research InstituteUniversity of AlbertaUniversity of Calgary
FundersH2020 European Research CouncilUniversity of California, San DiegoSamsungGenentechCrohn's and Colitis CanadaShionogiCelltrionCelgeneTeva Pharmaceutical IndustriesJanssen PharmaceuticalsGilead SciencesSanofiNational Institute of Diabetes and Digestive and Kidney DiseasesTillotts PharmaAmgenPfizerPatient-Centered Outcomes Research InstituteEli Lilly and CompanyBristol-Myers SquibbMylanGlaxoSmithKline
KeywordsMedicineInflammatory bowel diseaseComplete remissionRandomized controlled trialOpen labelInternal medicineUlcerative colitisSurgeryDiseaseChemotherapy

Abstract

fetched live from OpenAlex

INTRODUCTION: Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%-50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologically active bowel inflammation, and it is uncertain whether changing alternative advanced therapies in asymptomatic patients with IBD will reduce bowel inflammation and achieve durable deep remission. METHODS AND ANALYSIS: The QUality Outcomes Treating IBD to Target (QUOTIENT) study is an open-label, multicentre, pragmatic, randomised, controlled trial that aims to compare the efficacy and safety of switching to an alternative advanced therapy targeting endoscopic/radiological remission (treat-to-target) versus continuing the initial, or index, advanced therapy, in asymptomatic patients with IBD with moderate-to-severe endoscopic/radiological bowel inflammation. Enrolment is planned for ~250 participants in Canada/USA, randomised 1:1 to switching to alternative advanced therapy or continuing index advanced therapy, and then followed 104 weeks within routine clinical practice. Patient-reported outcomes measure efficacy and quality of life/treatment burden/safety. Primary endpoint is the time from randomisation to treatment failure. ETHICS AND DISSEMINATION: The study is conducted in compliance with the protocol, ICH Good Clinical Practice, applicable regulatory requirements and appropriate review boards/independent ethics committees (approval numbers: Pro00077486; Pro00061437; STUDY00002062; 22-004171; i22-01269; IRB22-0890; IRB_00154397; 2000032384; SHIRB#2022.095-2; STUDY00007146; MMC#2024-18; REB#125290; 17784; Pro00142214; 20240660-01H), with documented written informed consent. Findings will be disseminated through peer-reviewed journals, scientific presentations, and publicly available Patient-Centered Outcomes Research Institute (PCORI) websites, including lay summaries. The Crohn's & Colitis Foundation Education, Support, and Advocacy Department, and our patient advocacy stakeholder, will develop educational and marketing resources to communicate findings to a broad audience (>250 000 patients/caregivers/healthcare professionals). TRIAL REGISTRATION NUMBER: NCT05230173.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.077
metaresearch head score (Gemma)0.072
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.077
Threshold uncertainty score0.408

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0770.072
Meta-epidemiology (narrow)0.0060.003
Meta-epidemiology (broad)0.0090.006
Bibliometrics0.0030.004
Science and technology studies0.0030.006
Scholarly communication0.0060.004
Open science0.0040.003
Research integrity0.0100.008
Insufficient payload (model declined to judge)0.0360.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.328
Teacher spread0.312 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueBMJ Open GastroenterologySame topicInflammatory Bowel DiseaseFrench-language works237,207